VYNE Therapeutics (NASDAQ:VYNE) Second Quarter 2024 Results

Key Financial Results

• Net loss: US$9.40m (loss narrowed by 6.4% from 2Q 2023).

• US$0.22 loss per share (improved from US$3.07 loss in 2Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

VYNE Therapeutics Revenues Beat Expectations, EPS Falls Short

Revenue exceeded analyst estimates by 80%. Earnings per share (EPS) missed analyst estimates by 16%.

Looking ahead, revenue is forecast to grow 89% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US.

Performance of the American Pharmaceuticals industry.

The company's shares are up 5.1% from a week ago.

Risk Analysis

You still need to take note of risks, for example - VYNE Therapeutics has 6 warning signs (and 3 which make us uncomfortable) we think you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.